{"id":"mmf-ec-mps","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Diarrhea"},{"rate":"15-30","effect":"Nausea"},{"rate":"10-20","effect":"Vomiting"},{"rate":"15-25","effect":"Abdominal pain"},{"rate":"15-25","effect":"Leukopenia"},{"rate":"10-20","effect":"Anemia"},{"rate":"20-30","effect":"Infection"},{"rate":"5-15","effect":"Tremor"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:59:53.665180","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mycophenolate mofetil (MMF) and its active metabolite mycophenolic acid (MPA) inhibit IMPDH type II, an enzyme critical for guanosine nucleotide synthesis in lymphocytes. By depleting guanosine nucleotides, the drug preferentially blocks T and B cell proliferation while sparing other cell types, thereby reducing immune-mediated rejection of transplanted organs. EC-MPS (enteric-coated mycophenolate sodium) is a formulation designed to improve gastrointestinal tolerability.","oneSentence":"MMF/EC-MPS is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that selectively suppresses T and B lymphocyte proliferation to prevent organ rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:33.779Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in renal transplant recipients"},{"name":"Prevention of organ rejection in cardiac transplant recipients"},{"name":"Prevention of organ rejection in hepatic transplant recipients"}]},"_fixedFields":["pubmed(4)"],"trialDetails":[{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT06338306","phase":"","title":"Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-01-07","conditions":"Heart Transplant Failure","enrollment":25},{"nctId":"NCT05385432","phase":"PHASE3","title":"Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2023-09-12","conditions":"Renal Transplant Rejection, Induction Therapy","enrollment":244},{"nctId":"NCT05872568","phase":"PHASE4","title":"Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Zhishui Chen","startDate":"2023-06-01","conditions":"Kidney Transplant Rejection","enrollment":270},{"nctId":"NCT00149968","phase":"PHASE4","title":"Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-04","conditions":"Renal Transplantation, Gastrointestinal Problems","enrollment":196},{"nctId":"NCT01801280","phase":"PHASE4","title":"Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS","status":"COMPLETED","sponsor":"Klemens Budde","startDate":"2012-01","conditions":"Transplantation, Immunosuppression, Drug Interaction","enrollment":20},{"nctId":"NCT00862979","phase":"PHASE4","title":"A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02-24","conditions":"Heart Transplantation","enrollment":162},{"nctId":"NCT01044667","phase":"NA","title":"A Gastrointestinal Quality of Life Study in Lung Transplant Recipients Converted From Mycophenolate Mofetil to Myfortic","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2010-01","conditions":"Lung Transplantation","enrollment":3},{"nctId":"NCT00150007","phase":"PHASE4","title":"Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-06","conditions":"Kidney Maintenance Transplant","enrollment":335},{"nctId":"NCT00529269","phase":"PHASE4","title":"Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Renal Transplant","enrollment":200},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00425308","phase":"PHASE3","title":"Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Renal Transplantation","enrollment":30},{"nctId":"NCT00239005","phase":"PHASE4","title":"Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09","conditions":"Renal Transplant","enrollment":134},{"nctId":"NCT00284947","phase":"PHASE4","title":"Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-01","conditions":"Kidney Transplantation, Adverse Effects","enrollment":7},{"nctId":"NCT01284257","phase":"","title":"Observational Registry Study of Renal Transplant Patients","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2007-06","conditions":"Kidney Transplant","enrollment":""},{"nctId":"NCT00238446","phase":"PHASE3","title":"Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-04","conditions":"Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS","enrollment":""},{"nctId":"NCT00537862","phase":"PHASE4","title":"Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-05","conditions":"Kidney Transplant","enrollment":200},{"nctId":"NCT00154206","phase":"PHASE4","title":"Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-09","conditions":"Kidney Transplantation","enrollment":15},{"nctId":"NCT00239083","phase":"PHASE4","title":"Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-01","conditions":"Kidney Transplantation","enrollment":40},{"nctId":"NCT00240955","phase":"PHASE4","title":"Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-03","conditions":"Renal Transplantation","enrollment":79},{"nctId":"NCT00238953","phase":"PHASE4","title":"Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-02","conditions":"Renal Transplantation","enrollment":30},{"nctId":"NCT00154245","phase":"PHASE4","title":"A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-01","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT00400647","phase":"PHASE4","title":"Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-07","conditions":"Maintenance Kidney Transplant","enrollment":136},{"nctId":"NCT00229138","phase":"PHASE4","title":"Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09","conditions":"Kidney Transplantation","enrollment":291},{"nctId":"NCT01680861","phase":"PHASE3","title":"Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium","status":"COMPLETED","sponsor":"Gaetano Ciancio","startDate":"2012-11","conditions":"Transplant; Failure, Kidney","enrollment":32},{"nctId":"NCT00149942","phase":"PHASE4","title":"Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-10","conditions":"Kidney Transplantation, Liver Transplantation","enrollment":23},{"nctId":"NCT01625377","phase":"PHASE3","title":"A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Liver Transplantation","enrollment":188},{"nctId":"NCT01300416","phase":"","title":"Measurement of Patient Reported Outcomes in Renal Transplant Patients With And Without Gastrointestinal (GI) Symptoms","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-07","conditions":"Kidney Transplantation, GI Symptoms Severity","enrollment":101},{"nctId":"NCT00652834","phase":"PHASE4","title":"Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2009-04","conditions":"Gastrointestinal Lesions, Signs and Symptoms, Digestive","enrollment":23},{"nctId":"NCT01033864","phase":"PHASE4","title":"A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-11","conditions":"Kidney Transplantation","enrollment":23},{"nctId":"NCT01822483","phase":"PHASE4","title":"A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)","status":"COMPLETED","sponsor":"Irmandade Santa Casa de Misericórdia de Porto Alegre","startDate":"2013-04","conditions":"Renal Transplantation","enrollment":100},{"nctId":"NCT01044303","phase":"PHASE4","title":"Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)","status":"COMPLETED","sponsor":"East Carolina University","startDate":"2010-01","conditions":"Transplant; Failure, Kidney","enrollment":32},{"nctId":"NCT01015456","phase":"PHASE3","title":"The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis","status":"TERMINATED","sponsor":"Chulalongkorn University","startDate":"2010-01","conditions":"Lupus Nephritis","enrollment":59},{"nctId":"NCT00332839","phase":"PHASE4","title":"Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":"Renal Transplantation","enrollment":93},{"nctId":"NCT00965094","phase":"PHASE4","title":"Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12","conditions":"Chronic Renal Failure","enrollment":36},{"nctId":"NCT00634920","phase":"PHASE4","title":"Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-03","conditions":"Renal Function","enrollment":204},{"nctId":"NCT00154310","phase":"PHASE4","title":"Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":"Renal Transplantation","enrollment":300},{"nctId":"NCT00371826","phase":"PHASE4","title":"SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-03","conditions":"Renal Transplanted Recipients","enrollment":126},{"nctId":"NCT01213394","phase":"PHASE3","title":"Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients","status":"TERMINATED","sponsor":"Ramesh Prasad","startDate":"2010-10","conditions":"Kidney Transplantation, Cardiovascular Diseases","enrollment":2},{"nctId":"NCT00238992","phase":"PHASE3","title":"Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-12","conditions":"Kidney de Novo Transplant","enrollment":144},{"nctId":"NCT00284921","phase":"PHASE3","title":"MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-04","conditions":"De Novo Kidney Transplant","enrollment":60},{"nctId":"NCT00239044","phase":"PHASE3","title":"An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-12","conditions":"Kidney Transplant Recipients","enrollment":40},{"nctId":"NCT00154232","phase":"PHASE4","title":"Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-06","conditions":"Renal Transplantation","enrollment":46},{"nctId":"NCT00238979","phase":"PHASE4","title":"A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-01","conditions":"Renal Transplantation","enrollment":50},{"nctId":"NCT00574743","phase":"PHASE4","title":"Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-01","conditions":"Heart Transplantation","enrollment":162},{"nctId":"NCT00890253","phase":"PHASE2","title":"Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation","status":"UNKNOWN","sponsor":"Armin Goralczyk","startDate":"2010-01","conditions":"Liver Transplantation, Chronic Renal Insufficiency","enrollment":29},{"nctId":"NCT00400400","phase":"PHASE4","title":"Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Renal Transplantation","enrollment":400},{"nctId":"NCT01399242","phase":"PHASE4","title":"Efficacy of Certican® in Combination With Myfortic® in Renal","status":"UNKNOWN","sponsor":"Hospital Universitário São José","startDate":"2011-08","conditions":"Disorder Related to Renal Transplantation","enrollment":40},{"nctId":"NCT00423098","phase":"PHASE2","title":"Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-02","conditions":"Lupus Nephritis","enrollment":81},{"nctId":"NCT00267150","phase":"PHASE3","title":"Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":"Pancreas Transplantation, Kidney Transplantation","enrollment":31},{"nctId":"NCT00284934","phase":"PHASE3","title":"Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Kidney Diseases","enrollment":94},{"nctId":"NCT00351377","phase":"PHASE3","title":"Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-06","conditions":"Autoimmune Disease","enrollment":111},{"nctId":"NCT00413920","phase":"PHASE3","title":"Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Renal Transplantation","enrollment":222},{"nctId":"NCT00434590","phase":"PHASE4","title":"Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-03","conditions":"Kidney Transplantation","enrollment":10},{"nctId":"NCT00369278","phase":"PHASE3","title":"Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-06","conditions":"Renal Transplantation","enrollment":128},{"nctId":"NCT00405652","phase":"PHASE3","title":"Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Liver Transplantation","enrollment":34},{"nctId":"NCT00171379","phase":"PHASE3","title":"Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-03","conditions":"Prevention of Acute Rejection After Kidney Transplantation","enrollment":162},{"nctId":"NCT00312143","phase":"PHASE4","title":"Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-02","conditions":"De Novo Kidney Transplant Recipients","enrollment":35},{"nctId":"NCT00308425","phase":"PHASE3","title":"Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-10","conditions":"De Novo Renal Transplantation","enrollment":119},{"nctId":"NCT00238966","phase":"PHASE4","title":"Extension Study to Assess Tolerability and Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients Who Received Mycophenolate Mofetil","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-11","conditions":"Renal Transplantation","enrollment":187},{"nctId":"NCT00239031","phase":"PHASE3","title":"Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME in Eldery de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term Steroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-03","conditions":"Denovo Renal Transplantation","enrollment":117},{"nctId":"NCT00241059","phase":"PHASE4","title":"Extension Study of the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-08","conditions":"Renal Transplantation","enrollment":183},{"nctId":"NCT00239018","phase":"PHASE4","title":"Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-04","conditions":"De Novo Kidney Transplantation","enrollment":144},{"nctId":"NCT00238940","phase":"PHASE3","title":"Extension Study of Enteric-coated Mycophenolate Sodium in Combination With Full Dose or Reduced Dose Cyclosporine Microemulsion in Patients With de Novo Kidney Transplants","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-02","conditions":"Renal Transplantation","enrollment":55},{"nctId":"NCT00239070","phase":"PHASE3","title":"Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-04","conditions":"Renal Transplantation","enrollment":69},{"nctId":"NCT00239057","phase":"PHASE3","title":"Study of Enteric-coated Mycophenolate Sodium Maintenance Therapy in Patients With Renal Transplant Receiving Cyclosporine Microemulsion and Steroids,","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-05","conditions":"Maintenance Renal Transplantation","enrollment":23},{"nctId":"NCT01183247","phase":"PHASE4","title":"An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2008-07","conditions":"Comparative Study, Immunosuppressive Agents","enrollment":63},{"nctId":"NCT00611494","phase":"PHASE4","title":"Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients Treated With Calcineurin Inhibitors","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2008-01","conditions":"Organ Transplantation","enrollment":400},{"nctId":"NCT00468936","phase":"PHASE3","title":"Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms","status":"UNKNOWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2007-05","conditions":"Heart Transplant Patients","enrollment":100},{"nctId":"NCT00676221","phase":"PHASE4","title":"Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS)","status":"UNKNOWN","sponsor":"Foothills Medical Centre","startDate":"2006-07","conditions":"Kidney Transplant","enrollment":110},{"nctId":"NCT00150020","phase":"PHASE4","title":"Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-10","conditions":"Renal Transplantation","enrollment":728},{"nctId":"NCT00420472","phase":"PHASE4","title":"A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-03","conditions":"Kidney Transplantation","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"recentPublications":[{"date":"2016 Mar","pmid":"27110009","title":"The Cost of Gastrointestinal Adverse Events and the Impact of Dose-Reductions/Discontinuations on Acute Rejection in Kidney Transplant Patients of Mycophenolate Mofetil-Related Compared to Enteric-Coated Mycophenolate Sodium: A Pharmacoeconomic Study.","journal":"Transplantation proceedings"},{"date":"2015 Oct","pmid":"25752497","title":"Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres.","journal":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"date":"2009 Jul-Aug","pmid":"19715870","title":"Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications.","journal":"Transplantation proceedings"},{"date":"2009 May","pmid":"19460541","title":"Enteric-coated mycophenolate sodium: one-way conversion from mycophenolate mofetil and de novo use in stable liver transplant recipients.","journal":"Transplantation proceedings"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MPA","Myfortic","Cellcept"],"phase":"marketed","status":"active","brandName":"MMF/EC-MPS","genericName":"MMF/EC-MPS","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MMF/EC-MPS is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that selectively suppresses T and B lymphocyte proliferation to prevent organ rejection. Used for Prevention of organ rejection in renal transplant recipients, Prevention of organ rejection in cardiac transplant recipients, Prevention of organ rejection in hepatic transplant recipients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}